Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS (ALXN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/08/2017 12/11/2017 12/12/2017 12/13/2017 12/14/2017 Date
114.46(c) 111.9(c) 113.6(c) 113.54(c) 112.87 Last
5 486 737 2 625 239 1 611 091 1 873 365 810 601 Volume
+7.19% -2.24% +1.52% -0.05% -0.59% Change
More quotes
Financials ($)
Sales 2017 3 519 M
EBIT 2017 1 473 M
Net income 2017 528 M
Debt 2017 1 307 M
Yield 2017 -
Sales 2018 4 090 M
EBIT 2018 1 926 M
Net income 2018 998 M
Finance 2018 365 M
Yield 2018 -
P/E ratio 2017 47,79
P/E ratio 2018 25,43
EV / Sales2017 7,58x
EV / Sales2018 6,11x
Capitalization 25 366 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company was founded... 
Sector
Pharmaceuticals
Calendar
02/01Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
12/13 ALEXION PHARMACEUTICALS : Results of Phase 1b 2 Dose Regimen Optimization Studie..
12/11 ALEXION PHARMACEUTICALS : Results of Phase 1b/2 Dose Regimen Optimization Studie..
12/11 ALEXION PHARMACEUTICALS : and Halozyme Enter License Agreement for ENHANZE Techn..
12/08 ALEXION PHARMACEUTICALS : Elliott Management seeks changes at Alexion - NYT
12/08 NASDAQ 100 MOVERS : Viab, alxn
12/08 S&P 500 MOVERS : Coo, alxn
12/08 MARKETS RIGHT NOW : Jobs, Brexit progress send stocks higher
12/07 NASDAQ 100 MOVERS : Ctrp, viab
12/07 S&P 500 MOVERS : Hrb, viab
11/27 ALEXION PHARMACEUTICALS : to Present at the Citi 2017 Global Healthcare Conferen..
More news
Sector news : Biopharmaceuticals
12/13 TEVA PHARMACEUTICAL INDUSTRIES : Fears of Israeli job cuts at Teva sparks call f..
12/13 France's Sanofi pins hopes on new drugs after setbacks
12/13DJELI LILLY AND : Sees Modest Revenue Growth in 2018
12/13 SANOFI : CEO says M&A targets in oncology are 'very expensive'
12/13DJPLANT IMPACT : Needs Extra GBP7 Million Funding by April, Hands up 'For Sale' Si..
More sector news : Biopharmaceuticals
News from SeekingAlpha
12/13 ARGENX : This ASH Winner Has Further Upside Ahead
12/11 BIOTECH FORUM DAILY DIGEST : Revisiting Neos Therapeutics
12/11 Game Plan For The Week - Cramer's Mad Money (12/8/17)
12/08 Akari's Coversin successful in mid-stage PNH study
12/08 PREMARKET GAINERS AS OF 9 : 05 am
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 163 $
Spread / Average Target 44%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Julie O'Neill Executive Vice President-Global Operations
Paul J. Clancy Chief Financial Officer
John J. Orloff Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS-6.45%25 366
BIOGEN22.28%69 371
CSL LIMITED41.45%47 999
GRIFOLS SA27.54%17 919
BIOMARIN PHARMACEUTICAL-1.03%15 474
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%7 253